Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.
This week in oncology, the FDA expanded the treatment landscape for platinum-resistant ovarian cancer with a new approval, and significant clinical data emerged regarding novel in ...
Researchers reported at the 2026 European Lung Cancer Congress that Hernexeos (zongertinib) led to high response rates and ...
Purpose: To assess the distribution of neuroendocrine cells in the male penile urethra and the influence of age and estrogen therapy. Materials and methods: A retrospective immunohistochemical cohort ...
A recent integrative analysis of single-cell sequencing and single-cell spatial mapping of lymph node metastasis in breast cancer reveals novel mechanisms of the metabolic-immune interaction that ...
Therapy-resistant subclones as drivers of progression in aggressive variant prostate cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary Cancers Symposium. This abstract does not ...
Please provide your email address to receive an email when new articles are posted on . Neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin significantly benefited patients with ...
Real-world use of novel hormonal therapies in European and North American patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC). Outcomes of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) ...
A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with muscle-invasive bladder cancer, even those eligible for cisplatin ...
Abstract: Breast cancer remains a major global health challenge, while more efficient and low-cost diagnosis technologies are expected to explore, while Raman spectroscopy has been employed for breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results